Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Treatment of dyslipidemia in chronic kidney disease: Effectiveness and safety of statins.

Scarpioni R, Ricardi M, Albertazzi V, Melfa L.

World J Nephrol. 2012 Dec 6;1(6):184-94. doi: 10.5527/wjn.v1.i6.184. Review.

2.

Statins for treatment of dyslipidemia in chronic kidney disease.

Shurraw S, Tonelli M.

Perit Dial Int. 2006 Sep-Oct;26(5):523-39. Review.

PMID:
16973506
3.

HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.

Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Perkovic V, Hegbrant J, Strippoli GF.

Cochrane Database Syst Rev. 2014 May 31;(5):CD007784. doi: 10.1002/14651858.CD007784.pub2. Review.

PMID:
24880031
4.

[Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant].

Karie S, Launay-Vacher V, Deray G, Isnard-Bagnis C.

Presse Med. 2006 Feb;35(2 Pt 1):219-29. Review. French.

PMID:
16493350
5.

Statin treatment for dyslipidemia in chronic kidney disease and renal transplantation: a review of the evidence.

Kanbay M, Turgut F, Covic A, Goldsmith D.

J Nephrol. 2009 Sep-Oct;22(5):598-609. Review.

PMID:
19809992
6.

Statins and lipid-lowering strategies in cardiorenal patients.

Bianchi S, Grimaldi D, Bigazzi R.

Contrib Nephrol. 2011;171:143-50. doi: 10.1159/000327139. Epub 2011 May 23. Review.

PMID:
21625103
7.

HMG CoA reductase inhibitors (statins) for kidney transplant recipients.

Palmer SC, Navaneethan SD, Craig JC, Perkovic V, Johnson DW, Nigwekar SU, Hegbrant J, Strippoli GF.

Cochrane Database Syst Rev. 2014 Jan 28;(1):CD005019. doi: 10.1002/14651858.CD005019.pub4. Review.

PMID:
24470059
8.

Dyslipidemia in chronic kidney disease: are statins still indicated in reduction cardiovascular risk in patients on dialysis treatment?

Scarpioni R, Ricardi M, Melfa L, Cristinelli L.

Cardiovasc Ther. 2010 Dec;28(6):361-8. doi: 10.1111/j.1755-5922.2010.00182.x. Review.

PMID:
20553296
9.

Optimal management of combined dyslipidemia: what have we behind statins monotherapy?

Tenenbaum A, Fisman EZ, Motro M, Adler Y.

Adv Cardiol. 2008;45:127-53. doi: 10.1159/0000115192. Review.

PMID:
18230960
10.

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.

Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellström B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Grönhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R; SHARP Investigators..

Lancet. 2011 Jun 25;377(9784):2181-92. doi: 10.1016/S0140-6736(11)60739-3. Epub 2011 Jun 12.

11.

[Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].

Cases Amenós A, Goicoechea Diezhandiño M, de Alvaro Moreno F.

Nefrologia. 2008;28 Suppl 3:39-48. Spanish.

12.

Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease.

Sharp Collaborative Group.

Am Heart J. 2010 Nov;160(5):785-794.e10. doi: 10.1016/j.ahj.2010.08.012. Epub 2010 Sep 18.

PMID:
21095263
13.

Controversies Regarding Lipid Management and Statin Use for Cardiovascular Risk Reduction in Patients With CKD.

Markossian T, Burge N, Ling B, Schneider J, Pacold I, Bansal V, Leehey D, Stroupe K, Chang A, Kramer H.

Am J Kidney Dis. 2016 Jun;67(6):965-77. doi: 10.1053/j.ajkd.2015.12.030. Epub 2016 Mar 2.

PMID:
26943983
14.

LDL-cholesterol lowering and renal outcomes.

Waters DD.

Curr Opin Lipidol. 2015 Jun;26(3):195-9. doi: 10.1097/MOL.0000000000000176. Review.

15.

Statins and kidney disease: is the study of heart and renal protection at the cutting edge of evidence?

Jenkins M, Goldsmith D.

Curr Opin Cardiol. 2012 Jul;27(4):429-40. doi: 10.1097/HCO.0b013e328353b988. Review.

PMID:
22678410
16.

Statins in chronic kidney disease and kidney transplantation.

Kassimatis TI, Goldsmith DJ.

Pharmacol Res. 2014 Oct;88:62-73. doi: 10.1016/j.phrs.2014.06.011. Epub 2014 Jul 1. Review.

PMID:
24995940
17.
18.

HMG CoA reductase inhibitors (statins) for dialysis patients.

Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Perkovic V, Nigwekar SU, Hegbrant J, Strippoli GF.

Cochrane Database Syst Rev. 2013 Sep 11;(9):CD004289. doi: 10.1002/14651858.CD004289.pub5. Review.

PMID:
24022428
19.

Effects of lipid-lowering therapy on reduction of cardiovascular events in patients with end-stage renal disease requiring hemodialysis.

Marrs JC, Saseen JJ.

Pharmacotherapy. 2010 Aug;30(8):823-9. doi: 10.1592/phco.30.8.823. Review.

PMID:
20653359
20.

Ezetimibe as a potential treatment for dyslipidemia associated with chronic renal failure and renal transplant.

Ahmed MH, Khalil AA.

Saudi J Kidney Dis Transpl. 2010 Nov;21(6):1021-9. Review.

Supplemental Content

Support Center